Selank

Selank is a synthetic heptapeptide developed by combining the tuftsin sequence (Thr-Lys-Pro-Arg) with a stabilizing Pro-Gly-Pro C-terminal tripeptide. Like Semax, it was developed at the Institute of Molecular Genetics in Russia and has been extensively studied for its anxiolytic and nootropic properties.

Research indicates Selank may modulate the expression of brain-derived neurotrophic factor (BDNF) and influence GABAergic neurotransmission without causing sedation or dependence commonly associated with traditional anxiolytics. Studies have examined its potential effects on anxiety-related behaviors, cognitive performance, and immune function.

Selank has also been investigated for its immunomodulatory properties, with research suggesting it may influence cytokine balance and immune cell activity. Its dual action on both neurological and immunological systems makes it a unique research compound.